Repulsive guidance molecules (RGMs) control crucial processes including cell motility, adhesion, immune-cell regulation and systemic iron metabolism. RGMs signal via the neogenin (NEO1) and the bone morphogenetic protein (BMP) pathways. Here, we report crystal structures of the N-terminal domains of all human RGM family members in complex with the BMP ligand BMP2, revealing a new protein fold and a conserved BMP-binding mode. Our structural and functional data suggest a pH-linked mechanism for RGM-activated BMP signaling and offer a rationale for RGM mutations causing juvenile hemochromatosis. We also determined the crystal structure of the ternary BMP2-RGM-NEO1 complex, which, along with solution scattering and livecell super-resolution fluorescence microscopy, indicates BMP-induced clustering of the RGM-NEO1 complex. Our results show how RGM acts as the central hub that links BMP and NEO1 and physically connects these fundamental signaling pathways.
a r t i c l e s RGMs are glycophosphatidylinositol (GPI)-anchored glycoproteins. There are three mammalian family members: RGMA, RGMB (also known as DRAGON) and RGMC (also known as hemojuvelin, HFE2). RGM dysfunction is linked to regenerative failure 1 , inflammation 2 , multiple sclerosis 3 , cancer 4 and blood diseases 5 . RGMs were initially discovered as a repulsive axon-guidance cue 6 . They signal by binding to the cell-surface receptor NEO1 (refs. 7,8) , which belongs to the immunoglobulin superfamily and shares homology with the receptor deleted in colorectal cancer (DCC). We previously showed that this process is triggered by two RGM molecules that act as a molecular staple by bringing together the juxtamembrane regions of two NEO1 receptors, thus resulting in downstream signaling and actin cytoskeleton rearrangements 9 . All RGM family members have also been identified as co-receptors for the BMP morphogen pathway [10] [11] [12] , a process that was previously suggested to be modulated by NEO1 (refs. 13,14) .
BMPs compose the largest subgroup of the transforming growth factor β (TGFβ) superfamily and are key signaling players in embryonic development and in adult organisms 15 . The active BMP signaling complex consists of the BMP ligand, a constitutive disulfide-linked dimer, which concomitantly binds to the BMP type I and type II receptors. Four different BMP type I receptors (ALK1, ACVR1, BMPR1A and BMPR1B) and three BMP type II receptors (ACVR2A, ACVR2B and BMPR2) have been identified 16, 17 . Ligand binding triggers intracellular phosphorylation and activation of the type I receptor kinase domain by the constitutively active type II receptor kinase 18 . Subsequent downstream signaling occurs either via the SMAD signaling cascade 19 or via less well characterized alternative pathways 20 . The cellular localization and the site of action of TGFβ and BMP receptors are still under debate, and endocytosis has been shown to be important for TGFβ and BMP signaling 21 . BMP receptors (type I and II) undergo constitutive clathrin-mediated endocytosis even in the absence of the BMP ligand, thus resulting in a potentiation of SMAD-dependent BMP signaling upon BMP-ligand exposure 22 . Moreover, BMPR2 is also internalized through caveolae, and the balance between caveola-and clathrin-mediated endocytosis has been suggested to modulate the patterns of gene transcription initiated by BMP signaling 22, 23 . In addition to endocytosis of the BMP receptors, internalization of the BMP ligand has also been observed 24 , and components of the SMAD signaling cascade are recruited to endosomal structures for activation 25 .
Multiple effector proteins act to regulate and fine-tune spatiotemporal BMP signaling at the membrane 26 . These include soluble secreted antagonists (such as Noggin, Chordin and the DAN or Cerberus protein family), transmembrane proteins (for example, BAMBI and Endoglin) and the membrane-attached RGM family. RGMs are important co-receptors and activators for BMP signaling. RGMA and RGMB were initially identified in cellular BMP reporter assays 11, 12 . In addition, RGMB negatively regulates interleukin-6 expression in macrophages in a BMP ligand-dependent manner 27 . RGMC has been shown to enhance BMP signaling in liver cells, thus upregulating hepcidin expression and thereby controlling blood iron levels 10 , and mutations in RGMC cause the blood iron-overload disease juvenile hemochromatosis (JHH) 5, 28, 29 , a pathology resulting from impaired BMP signaling 10, 30 . All RGMs can bind directly to BMPs with nanomolar affinities 31, 32 ; however, the molecular mechanism by which RGMs activate BMP signaling and the role of NEO1 in these processes have remained unclear.
To validate our structural data, we carried out surface plasmon resonance (SPR) equilibrium binding experiments ( Fig. 2d-g) . Our SPR analysis revealed a level of nonspecific interaction between RGMs and BMP2, an effect that was markedly decreased for the N-terminal-domain RGM constructs. Both the full-length RGM ectodomain constructs (eRGMA, eRGMB and eRGMC) and the RGM N-terminaldomain constructs (RGMA ND , RGMB ND and RGMC ND ) bound to BMP2 with nanomolar affinities (the tightest being RGMB ND , with a K d of 88 nM), thus demonstrating that the RGM N-terminal domain is sufficient for interaction with BMP2 ( Fig. 2d,e and Supplementary  Fig. 4 ). In addition, mutation of RGMC H104 to alanine impaired binding to BMP2 (from a K d of 124 nM to a K d of 280 nM) ( Fig. 2e and Supplementary Fig. 4f,g) . This confirmed that the conserved RGMC H104 is important for efficient complex formation through a π-stacking interaction with BMP2 W313; we observed a similar behavior for the RGMB H106R mutation (Supplementary Fig. 4l ).
We also solved crystal structures of BMP2 in complex with the N-terminal domains of human RGMA and RGMB (RGMA ND and RGMB ND , respectively) ( Fig. 3 and Table 1 ). A structural superposition revealed that the overall complex architecture ( Fig. 3a) and BMP2 binding mode ( Fig. 3b-e ) is highly conserved across all RGM family members and across species ( Supplementary Fig. 1) , demonstrating a common mode for the BMP-RGM interaction. c   II   III   III   III   III   I   II   II   I   II   I   IV   I a r t i c l e s npg a r t i c l e s The RGMC-BMP2 structure offers a rationale for JHH mutations JHH is an autosomal-recessive iron-overload disorder that results in cardiomyopathy and diabetes. JHH is caused by a deficiency in the levels of hepcidin, whereas an excess of hepcidin is linked to anemia of inflammation 36, 37 . RGMC-activated BMP signaling is crucial for upregulation of hepcidin expression and control of serum iron levels, and mutations in RGMC are the major cause of JHH 5, 10 . Most of these mutations are located in the C-terminal domain of RGMC, the region responsible for NEO1 binding 9 (Fig. 1a) . These mutations impair protein secretion in mammalian cells, whereas mutations located in the RGMC N-terminal domain do not affect secretion 9, 38 . Here, we show that two of these, RGMC G99R and L101P, are located in the interface with BMP2 and reduce the affinity of the RGMC-BMP2 interaction (K d of 910 nM and 1.5 µM respectively) ( Fig. 2f,g and Supplementary Fig. 4h ,i). This not only validates the interface observed in our RGM ND -BMP2 structures but also suggests that disruption of the BMP-RGMC interaction is the molecular mechanism for JHH disease pathology. When taken together, our analyses may provide a basis for the structureguided design of new therapeutics for the treatment of iron-related disorders such as hemochromatosis and anemia of inflammation.
RGM competes with the BMP type I receptor for BMP2 binding
Crystal structures of BMP ligands with their respective receptor ectodomains have revealed a common mode of binding in which two BMP Figure 3 The mode of RGM-BMP2 interactions is conserved in RGMA, RGMB and RGMC. (a) Superposition of structures of the BMP2-RGMA ND , BMP2-RGMB ND and BMP2-RGMC ND complexes, with the BMP2 dimer as reference. BMP2 dimer is shown as solvent-accessible surface. RGMA (blue), RGMB (yellow) and RGMC (orange) are depicted as ribbons. Orientation is as in Figure 1d . type I and II receptor molecules bind independently to a BMP dimer in a symmetric arrangement [39] [40] [41] . In our RGM-BMP2 structures, RGM ND unexpectedly shares an overlapping BMP2-binding interface with the ectodomain of the BMP type I receptor BMPR1A (eBM-PR1A; Fig. 4a,b) ; however, the BMP2-binding site of the BMP type II receptor (eBMPR2 or eACVR2A) does not overlap ( Fig. 4a) . To confirm this observation drawn from our structural analyses, we carried out a series of SPR experiments. The secreted ectodomain of BMPR1A (eBMPR1A) bound to BMP2 with a K d of 280 ± 10 nM ( Fig. 4c) Supplementary Fig. 4b,e ). In this experimental setup, we did not detect specific binding between eRGMB and BMPreceptor ectodomain constructs (eBMPR1A, eBMPR2 and eACVR2A; Supplementary  Fig. 4p-r) , in contrast to previously reported pulldown experiments with full-length BMP receptors 11 . Next, we tested the ability of eBMPR1A to compete with eRGMB for BMP2 binding (Fig. 4d) . We observed that a 1.7-fold molar excess of eBMPR1A was required to displace eRGMB in solution, a result suggesting that eRGMB effectively competes with eBMPR1A for BMP binding, as expected from our structural data.
The RGM-BMP2 interaction is pH dependent
Although the structures of eBMPR1A and RGM ND are distinct, both share a common helix located at the interface with BMP2 ( Fig. 4a,b) , which is part of the BMPR1A site previously identified to be crucial for BMP2 interaction 43 . In this key helix, RGMB H106 (corresponding to RGMC H104) occupies the equivalent position to BMPR1A F108. Both residues are involved in π-stacking interactions with BMP2 residues W310 and W313 ( Figs. 3e and 4b) . With the hypothesis that the protonation state of RGMB H106 might affect the BMP2 W313 π-stacking, we performed multiangle light-scattering (MALS) measurements of both BMP2-RGMB ND and BMP2-eBMPR1A complexes at different pH values ( Fig. 4e,f) . For BMP2-RGMB ND , we observed a major species at neutral pH with a molecular weight corresponding to the 2:2 BMP2-RGM ND complex, whereas at pH 6.5 or lower dissociation of the complex occurred ( Fig. 4e) . Our data showed that the BMP2-RGMB ND interaction is pH dependent, whereas the BMP2-eBMPR1A interaction is not ( Fig. 4f ).
RGMB and BMPR1A differentially alter BMP signaling
How does RGM activate BMP signaling when it competes with the canonical BMP binding mode for BMP type I receptors?
In order to answer this, we conducted a BMP-responsive luciferase reporter (BRE-Luc) assay in LLC-PK1 cells 11, 44 . Stimulation with 6 nM purified BMP2 increased BRE-Luc activity to approximately five-fold (n = 40, P < 0.0001) over the control (Fig. 4g) . When we transfected cells with full-length (GPI-anchored) RGMB, BRE-Luc activity was further enhanced to approximately three-fold (n = 40, P < 0.0001) ( Fig. 4g) , comparably to previously published results 11 , whereas transfection with a GPI-anchored RGMB construct lacking the RGMB ND domain (RGMB ∆N ) had no effect (n = 40, P = 0.0509) on the BMPinduced response (Fig. 4g) . This confirmed that the N-terminal domain is necessary for this activation, results concordant with our structural and SPR analyses (Fig. 3d,e and Supplementary Fig. 4j ).
Next, we investigated the effects of soluble proteins (lacking the membrane-attachment sites) in the same luciferase reporter assay ( Fig. 4h and Supplementary Fig. 5 ). Stimulation with 6 nM purified BMP2 increased BRE-Luc activity to approximately ten-fold (n = 72, P < 0.0001) over the control (n = 37) ( Fig. 4h) . When we transfected cells with soluble eBMPR1A, BRE-Luc activity decreased to ~75% (n = 22, P < 0.0001). In contrast, transfection with soluble eRGMB and RGMB ND did not reduce BRE-Luc activity (n = 22, P = 0.8606; n = 24, P = 0.992, respectively) ( Fig. 4h and Supplementary Fig. 5 ), results contrasting with those from previous studies using an RGMB-Fc fusion construct 11 . To further validate our observation, we performed similar experiments but added purified eBMPR1A or eRGMB proteins directly to LLC-PK1 or C2C12 cells (Supplementary Fig. 5 ). Again, we observed inhibition of BMP signaling by eBMPR1A, whereas eRGMB did not inhibit BMP2 signaling in either cell type, even at concentrations (2.5 µM) three times the K d for the eRGMB-BMP2 interaction (Supplementary Fig. 5 ). In summary, soluble BMPR1A ectodomain acts as a 'ligand trap,' competing with endogenous BMP type I receptors and inhibiting signaling, as expected. Surprisingly, however, we found that this behavior does not extend to soluble RGMB proteins that nonetheless have similar binding affinities and can compete with the BMPR1A-BMP2 interaction. This finding, linked with the pH dependence of the RGMB-BMP2 interaction, may imply an endocytosis-linked mechanism of RGM-activated BMP signaling.
Structure of the ternary BMP-RGM-NEO1 complex
To place the RGM-BMP2 interaction into the context of the RGM-NEO1 signaling hub 9 , we next determined the crystal structure of the ternary complex composed of BMP2, eRGMB and the juxtamembrane region of NEO1 including the fifth (FN5) and sixth (FN6) fibronectin type III domains (Fig. 5a,b) . In the complex, a disulfide-linked BMP2 dimer binds to two molecules of RGMB ND in a very similar arrangement to that observed in the binary BMP2-RGMB ND complex (r.m.s.d. of 0.799 Å for 328 equivalent Cα positions) ( Supplementary  Fig. 6a ). Each RGMB ND is connected to the RGMB C-terminal domain (RGMB CD ) via a disordered 15-residue linker not visible in the electron density map. RGMB CD interacts with NEO1 via a similar mode to that observed for the major interaction site in the previously determined structure of the eRGMB-NEO1 complex 9 (r.m.s.d. of 0.511 Å for 368 equivalent Cα positions) ( Supplementary  Fig. 6a ). In the ternary complex, the FN5 domain of NEO1 also contacts BMP2 (Fig. 5a) . However, analysis of the observed interfaces (Supplementary Fig. 6b ) suggests that this NEO1-BMP2
interaction is due to crystal packing rather than to an important biological interface; this would also be consistent with the similar binding affinities of BMP2 to eRGMB or the purified eRGMB-NEO1 complex and the lack of increase in affinity contributed by NEO1 (Supplementary Fig. 4k) .
To test whether a similar arrangement of the RGMB-NEO1-BMP2 complex exists in solution, we carried out small-angle X-ray scattering (SAXS) experiments of the eRGMB-NEO1-BMP2 complex and its components ( Fig. 5c and Supplementary Fig. 7) . The eRGMB-NEO1-BMP2 complex, prepared via size-exclusion chromatography (Supplementary Fig. 7a,b ), resulted in a particle with a mass consistent with the ternary complex in a 2:2:2 stoichiometry. Starting from the crystal structure, we generated ensembles of RGMB-NEO1-BMP2 models by molecular dynamics sampling and selected these against the SAXS data. The solution structure can be accurately described (χ 2 = 1.9) as a mixture of two models that have architectures similar to the crystal structure but that show structural variation only at the level of the linker that connects RGMB ND and RGMB CD and thereby dislocates the NEO1-FN5 domain away from BMP2 (Fig. 5c) ; this supports our analysis of the observed interfaces in this complex interaction network (Supplementary Fig. 6b ).
BMP mediates clustering of RGM-NEO1 at the cell surface
In the ternary complex, the two RGM and NEO1 molecules are oriented in such a way that the C termini (which, in the context of the full-length proteins, are connected with the lipid bilayer of the plasma membrane) point in the same direction (Fig. 5b) . This arrangement, also observed in solution, combined with the active signaling conformation of the 2:2 complex between NEO1 and the C-terminal domain of RGM 9 , suggests a mode of clustering in which RGM bridges the dimers of BMP and NEO1 (Fig. 5d) . Indeed, total internal reflection npg a r t i c l e s fluorescence microscopy (TIRFM) combined with direct stochastic optical reconstruction microscopy (dSTORM) 45 in COS7 cells (Fig. 6a,b) revealed an increase in the clustering of fluorescently tagged NEO1 molecules in a time-dependent manner after the addition of 20 nM BMP2 with live ( Fig. 6a-f ) and fixed (Fig. 6g,h) cells. This clustering was dependent on the presence of full-length RGMB and reached a maximum ~15 min after addition of BMP2 ( Fig. 6e-h) .
DISCUSSION
RGMs can signal through both trans (intercellular) 9 and cis (same-cell) interactions. Cis signaling occurs in a BMP-dependent manner, such as in chondrocytes 46 and hepatocytes 14 , when both NEO1 and RGM are expressed on the same cell surface. Although the role of NEO1 in BMP signaling is still unclear and cell-type dependent 47 , multiple lines of evidence point toward a central role for the NEO1-RGM interaction in controlling BMP ligand-receptor localization. In hepatocytes, NEO1 inhibits RGMC shedding, thus enhancing BMP signaling and hepcidin expression in the liver 13, 14 . This is in agreement with our results in which high local RGM concentrations were required for activation of BMP in a luciferase reporter assay (Fig. 4g,h) . In vivo, such concentrations are probably provided only by membrane attachment of RGMs to BMP-responsive cells. Furthermore, SMAD-dependent BMP signaling is reduced in chondrocytes in NEO1-deficient mice, and NEO1 regulates BMP-receptor localization in membrane microdomains, an interaction that is potentially mediated by RGMs 46 . It is interesting to note that NEO1 is located in membrane microdomains in the growth cones of axons, a process that is dependent on the presence of both RGM and BMP signaling 48 . Our structural and functional data identify the RGM N-terminal domain as being the site of direct interaction for the BMP ligand. This interaction is accommodated in the multidomain architecture of our NEO1-RGM-BMP2 ternary-complex structure, which allows simultaneous binding of RGMs to NEO1 and BMP ligands and results in RGM-mediated clustering by bridging dimers of NEO1 and BMP2. Our luciferase reporter data, together with the pH dependence of the RGMB-BMP2 interaction, suggest a potential mechanism for RGM-mediated activation of BMP signaling. We showed that soluble eBMPR1A acts as an inhibitor of BMP signaling, whereas eRGMB does not. We propose that this difference is linked to the pH dependence of the RGMB-BMP2 interaction and the subcellular localization of the BMP signaling complexes. Upon clathrin-mediated endocytosis, BMP2-RGMB complexes might be targeted into endosomes, which are enriched with BMP type I receptors 22 . The acidification of the endosomes might then promote dissociation of RGMB from the complex and replacement by the BMP type I receptor, thus leading to enhanced BMP signals due to potentiation of SMAD signaling provided by the endosomal environment compared to the cell surface 21, 22 . In this scenario, the RGM-NEO1 complex could act as a shuttle for the BMP ligand (and potentially BMP type II receptors, which can be accommodated in our RGM-NEO1-BMP complex). The RGM-NEO1 complex potentially sequesters the BMP ligand at the membrane, priming it for transport via endosomal pathways. Future work will be required to test our hypothesis linking RGMs to BMP endocytosis and to characterize this in different biological contexts. Translocation of the signaling machinery through established pathways to place it in proximity to the nucleus, and therefore to downstream effector targets, is a very efficient way of effecting changes in gene expression. This mechanism has been suggested for other signaling pathways including the closely related TGFβ signaling 21 as well as signaling by epidermal growth factor 49 and glial cell-derived neurotrophic factor 50 . The molecular mechanism of RGM-mediated BMP activation, based on endocytosis of the entire signaling complex, may provide a paradigm for many 'cell surface' signaling events.
METHODS

Methods and any associated references are available in the online version of the paper.
Accession codes. Atomic coordinates and structure factors for RGMA ND -BMP2 (PDB 4UHY), RGMB ND -BMP2 form 1 (4UHZ), RGMB ND -BMP2 form 2 (4UI0), RGMC ND -BMP2 (4UI1) and eRGMB-BMP2-NEO1 FN56 (4UI2) have been deposited in the Protein Data Bank.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS
Expression and purification of RGMs, NEO1 and BMP-receptor constructs.
Constructs of the extracellular region of human RGMA (GenBank AL136826; RGMA ND aa 45-139), human RGMB (GenBank AK074887; eRGMB aa 53-412, RGMB ND aa 53-136, and RGMB-∆N aa137-412) human RGMC (GenBank AY372521; eRGMC aa 36-400 and RGMC ND aa 36-147), human BMPR1A (GenBank AK291764; eBMPR1A aa 49-141), human ACVR2A (GenBank X63128; eACVR2A aa 27-118), human BMPR2 (GenBank Z48923; eBMPR2 aa 33-132) and mouse NEO1 (GenBank Y09535; NEO1 aa 37-1493, NEO1 FN56 aa 883-1083 (ref. 51) , and NEO1 FN56M aa 883-1134 (ref. 51)), C-terminally fused with a hexahistidine, a BirA-recognition sequence, or an mVenus tag, were cloned into the pHLsec vector 52 and expressed by transient transfection in HEK-293T cells (ATCC CRL-11268) (with a semi-automated procedure 53 ) in the presence of the class I α-mannosidase inhibitor kifunensine 54 . Five days after transfection, the conditioned medium was dialyzed (48 h, 4 °C) against PBS, and the proteins were purified by immobilized metal-affinity chromatography with TALON beads (Clontech) and, for crystallization, treated with endoglycosidase F1 (75 µg mg −1 protein, 12 h, 21 °C) to cleave glycosidic bonds of N-linked sugars and result in only one N-acetylglucosamine moiety bound to the corresponding asparagine side chain. The proteins were concentrated and further purified by size-exclusion chromatography (SEC) (Superdex 200 16/60 column, GE Healthcare) in buffer containing 10 mM HEPES, pH 7.5, and 150 mM NaCl. The production of NEO1 FN56 and NEO1 FN56M followed a protocol described previously 51 .
Expression and purification of BMP2 and formation of protein complexes.
BMP2 was expressed as inclusion bodies and purified as follows (protocol adapted from ref. 55) . After cell lysis, inclusion-body pellets were washed four times with 20 mM EDTA, 2% (v/v) Triton X-100, and 500 mM NaCl, pH 7, and then solubilized in 6 M guanidinium hydrochloride (GdmHCl), 0.1 M Tris-HCl, pH 8.5, 1 mM EDTA and 100 mM DTT. The pH was dropped to 3-4 to inhibit disulfidebond formation. Residual insoluble material was removed by centrifugation (10 min, 10,000g, 4 °C). DTT was removed by dialysis four times against a 10-to 20-fold volume of 6 M GdmHCl, pH 3-4. Refolding was carried out by incubation of the reduced and solubilized inclusion-body preparation (24 h, 4 °C, ~200 µg/ml concentration) in 100 mM Tris-HCl, 5 mM EDTA, 1 M L-arginine, pH 8.3, 100 µM oxidized glutathione (GSSG), and 100 µM reduced glutathione (GSH). The sample was concentrated to 1 mg/ml with Amicon pressure filtration (Millipore) and the reaction split into two halves, one of which was oxidized with 25 mM GSSG (3 h, 4 °C). Excess GSSG was removed by dialysis, and the two reaction halves were combined. This sample was concentrated and applied to a heparin column (5 ml HiTrap Heparin HP, GE Healthcare) and then subjected to SEC in 4 M urea, 100 mM Tris-HCl, pH 6.0, and 5 mM EDTA. SEC fractions were analyzed by nonreducing SDS-PAGE, and those with a purity >95% of the dimeric species were pooled. BMP2-RGM ND complexes were formed by mixture of the proteins in a 1:1 molar ratio. For the ternary BMP2-eRGMB-NEO1 FN56 complex, BMP2 was mixed in equimolar amounts with a previously SEC-purified eRGMB-NEO1 FN56 complex. The complex mixtures were incubated for 1 h at room temperature before crystallization and concentrated to the appropriate concentration.
Site-directed mutagenesis. Site-directed mutagenesis of RGM proteins to test the specificity of protein-protein interactions was carried out by two-step overlapextension PCR with Pyrobest Polymerase (Takara). PCR products were cloned into the pHLsec vector as described above 52 . Mutant RGM proteins were secreted at similar levels to the respective wild-type constructs (data not shown). The stringent quality-control mechanisms specific to the mammalian cell secretory pathway is likely to ensure that secreted proteins are correctly folded 56 .
Crystallization and data collection. Prior to crystallization, complexes were concentrated (RGMA ND -BMP2, 6 mg/ml; RGMB ND -BMP2, 6 mg/ml; RGMC ND -BMP2, 5 mg/ml; and BMP2-eRGMB-NEO1 FN56 , 5 mg/ml). Crystallization trials, with 100 nl protein solution plus 100 nl reservoir solution in sitting-drop vapor-diffusion format were set up in 96-well Greiner plates with a Cartesian Technologies robot 57 . Crystallization plates were maintained at 6.5 or 20.0 °C in a TAP Homebase storage vault and imaged via a Veeco visualization system 58 . All RGM-BMP2 binary-complex crystals were grown at 6.5 °C, whereas the BMP2-eRGMB-NEO1 FN56 ternary complex was crystallized at 20 °C. RGMA ND -BMP2 crystals were obtained out of mother liquor containing 0.1 M citric acid, pH 4.0, 20% (v/v) 2-methyl-2,4-pentanediol (MPD), and 0.2 M glycine; RGMB ND -BMP2 form 1 crystals out of 2 M ammonium sulfate and 8% (v/v) 2,5-hexanediol; RGMB ND -BMP2 form-2 crystals out of 0.08 M citric acid, pH 4.0, and 15% (v/v) MPD; RGMC ND -BMP2 crystals out of 20% (w/v) PEG3350 and 0.2 M ammonium nitrate; and BMP2-eRGMB-NEO1 FN56 crystals out of 0.1 M Tris-HCl, pH 8.5, 1.5 M ammonium sulfate, and 12% (v/v) glycerol. Diffraction data were collected at 100 K at the following wavelengths: RGMA ND -BMP2, 1.0163 Å; RGMB ND -BMP2 form 1, 0.97620 Å; RGMB ND -BMP2 form 2; 0.91730 Å; RGMC ND -BMP2, 0.97625 Å; and BMP2-eRGMB-NEO1 FN56 , 0.97625 Å. Prior to flash-freezing, crystals were treated with the appropriate cryoprotectant solutions (RGMA ND -BMP2 and RGMB ND -BMP2 form-2, 30% (v/v) MPD in mother liquor; RGMB ND -BMP2 form-1 and RGMC ND -BMP2, 30% (v/v) ethylene glycol in mother liquor; and BMP2-eRGMB-NEO1 FN56 , 15% (v/v) glycerol in mother liquor). Data were collected at beamline I03 (RGMA ND -BMP2, RGMB ND -BMP2 form-1, and RGMC ND -BMP2), I04 (BMP2-eRGMB-NEO1 FN56 ) and I04-1 (RGMB ND -BMP2 form-2) at the Diamond Light Source, UK. X-ray data were processed and scaled with the HKL suite 59 and XIA2 (refs. [60] [61] [62] [63] [64] [65] . Data collection statistics are shown in Table 1 .
Structure determination and refinement. The RGMC ND -BMP2 complex was solved by molecular replacement in PHASER 66 with the structure of the disulfide-bonded BMP2 dimer (PDB 3BMP 67 ) as a search model. Extra electron density for two molecules of RGMC ND in the asymmetric unit was immediately discernible after density modification in PARROT 68 ( Supplementary  Fig. 2a,b) . The RGMC polypeptide chain was traced with iterative rounds of BUCCANEER 69 , manual building in COOT 70 and refinement in autoBUSTER (https://www.globalphasing.com/buster/) and PHENIX 71 . This resulted in a well-defined model for the RGMC ND -BMP2 complex that included two molecules of RGMC (residues Q36-P129) bound to a disulfide-linked BMP2 dimer (residues K293-R396) (Supplementary Fig. 2c) . The RGMA ND -BMP2 and RGMB ND -BMP2 complexes were solved by molecular replacement with PHASER with the RGMC ND -BMP2 complex as a search model. Molecular replacement with PHASER was applied to solve the BMP2-eRGMB-NEO1 FN56 structure with the RGMB ND -BMP2 form 1 (from this study) and the NEO1 FN56 -RGMB (PDB 4BQ6 (ref. 51)) structures. The complexes were refined with autoBUSTER (https://www.globalphasing.com/buster/) and PHENIX 71 , and, where applicable, noncrystallographic restraints were applied. For the BMP2-eRGMB-NEO1 FN56 structure, target weight refinement with the individual high-resolution structures of the BMP2, RGMB ND , eRGMB, NEO1 FN5 and NEO1 FN6 domains as targets was applied. Crystallographic statistics are given in Table 1 . Stereochemical properties were assessed by MOLPROBITY 72 . Superpositions were calculated with COOT 70 , and electrostatic potentials were generated with APBS 73 as implemented in PyMOL (http://www.pymol.org/). Buried surface areas of protein-protein interactions were calculated with the PISA webserver 74 for a probe radius of 1.4 Å.
Small-angle X-ray scattering (SAXS). Data were collected at beamline BM29 of the European Synchrotron Radiation Facility (ESRF, Grenoble, France) 75 at 293 K within a momentum transfer (q) range of 0.01 Å −1 < q < 0.45 Å −1 , where q = 4πsin(θ)/λ, and 2θ is the scattering angle. The X-ray wavelength was 0.0995 nm, and data were collected on a Pilatus 1M detector. Protein samples were measured at the following concentrations: NEO1 FN56M , 1.06 and 4.94 mg/ml; eRGMB, 0.96 and 5.48 mg/ml; NEO1 FN56M -eRGMB, 0.51 and 1.01 mg/ml; and BMP2-eRGMB-NEO1 FN56M , 0.68 and 1.14 mg/ml. Data reduction and calculation of invariants was carried out with the ATSAS suite 76 . A merged data set was obtained by combining the low-angle part of the low-concentration data set with the high-angle part of the high-concentration data set. Molecular-weight determination was performed with the volume of correlation metric V C with Scatter 77 . The BMP2-eRGMB-NEO1 FN56M solution structure was modeled starting from the crystal structure of the ternary complex. A structural model for C-terminal eRGMB residues His335-Ser410 (not observed in the electron density) was calculated with ROSETTA3. 5 (ref. 78) , constrained by imposing α-helical secondary structure and a disulfide bond between Cys358 and Cys372. Missing loops and N and C termini were added in extended conformations with Modeller 79 . Starting models for NEO1 FN56M , eRGMB, and the eRGMB-NEO1 FN56M binary subcomplex were then extracted from the completed BMP2-eRGMB-NEO1 FN56M model. All-atom ensemble modeling of NEO1 FN56M , eRGMB, eRGMB-NEO1 FN56M npg and BMP2-eRGMB-NEO1 FN56M was performed with AllosMod 80 , and in each case 50 independent ensembles of 100 models were generated. From this pool, automated selection of the minimal set of models satisfying the scattering data was performed with MES 81 , and calculation and fitting of scattering patterns were performed with FoXS 82 . This procedure was automated with the AllosMod-FoXS web server 83 . The solution structures of NEO1 FN56M , eRGMB, eRGMB-NEO1 FN56M and BMP2-eRGMB-NEO1 FN56M are described by one, one, three and two models, respectively.
Multiangle light scattering (MALS).
MALS experiments were carried out with a DAWN HELEOS II (Wyatt Technology), equipped with a K5 flow cell and a 30 mW linearly polarized GaAs laser with a wavelength of 690 nm. Proteins used for MALS contained wild-type sugars. Proteins were purified by SEC, and the BMP2-RGMB ND and BMP2-eBMPR1A complexes were formed by mixture of the components in a 1:1 molar ratio. Complexes were dialyzed against buffers generated with the malic acid, MES, Tris (MMT) buffer system (Molecular Dimensions): 10 mM MMT, pH 5.5/6.5/7.5, and 150 mM NaCl. Complexes were concentrated to 2 mg/ml before MALS analysis. Data were analyzed with ASTRA (Wyatt Technologies), and molecular weights were calculated with the Debye fit method. Molecular weights were calculated as: BMP2-RGMB ND , pH 7.5, 46.2 ± 2.7 and 22.4 ± 0.9; BMP2-RGMB ND , pH 6.5, 20.1 ± 1.4 and 13.4 ± 0.4; BMP2-RGMB ND , pH 5.5, 24.0 ± 1.2 and 16.2 ± 0.3; BMP2-eBMPR1A, pH 7.5, 53.0 ± 0.1 and 15.0 ± 0.2; BMP2-eBMPR1A, pH 6.5, 53.2 ± 0.3 and 18.8 ± 0.1; and BMP2-eBMPR1A, pH 5.5, 54.2 ± 0.5 and 19.7 ± 0.4. These molecular weights correspond to the following calculated masses: BMP2-RGMB ND , 47 kDa; BMP2, 26 kDa; RGMB ND , 11 kDa; BMP2-eBMPR1a, 53 kDa; and eBMPR1a, 14 kDa. Graphs were produced with GraphPad Prism Version 6.04 (GraphPad Software).
Surface plasmon resonance (SPR) binding studies. SPR experiments were performed with a BIAcore T200 machine (GE Healthcare) at 25 °C in SPR running buffer (10 mM HEPES, pH 7.5, 150 mM NaCl, and 0.005% (v/v) polysorbate 20). All experiments were performed with direct protein immobilization by amine coupling to CM5 biosensor chips except for those in Supplementary  Figure 5m -o, in which biotinylated eRGMB was immobilized onto streptavidincoupled CM5 biosensor chips 84 . Analytes were dialyzed against SPR running buffer before use, and 1:2 dilution series were prepared. For the competition experiment, a 1:2 dilution series of a mixture of 20 µM eBMPR1A and 2.5 µM eRGMB was prepared in buffer containing 2.5 µM eRGMB, to result in a dilution series of eBMPR1A in a constant (2.5 µM) concentration of eRGMB. BMP2 surface concentrations were 150, 500 and 1,000 response units. Surfaces coupled with BMP2 were regenerated by bursts of 4 M urea, 50 mM Tris, pH 8.0, and 150 mM NaCl (120s, 20 µl/min) and the experimental trace returned to baseline. In all experiments, error range is s.e.m. The signal from experimental flow cells was corrected by subtraction of the nearest blank injection and the reference signal from a blank flow cell. All data were analyzed with SCRUBBER2 (Biologic) and GraphPad Prism Version 6.04 (GraphPad Software). Best-fit binding curves were calculated for BMP2-BMP receptor interactions with nonlinear curve fitting of a 'one-site specific binding' model (Y = B max × X/(K d + X); X, analyte concentration; B max , maximum analyte binding). For BMP2-RGM binding, best-fit curves were calculated with nonlinear curve fitting of a 'one-site total binding' model (Y = B max × X/(K d + X) + NS × X + background; X, analyte concentration; background = 0 because data were already referenced). Nonspecific binding is proportional to analyte concentration, and therefore NS is the slope of nonspecific binding. B max and K d values were determined for the specific binding component only. For the eBM-PR1A-eRGMB competition experiment, a best-fit binding curve was calculated with a 'log(agonist) versus response variable slope' model (Y = bottom + (topbottom)/(1 + 10 (logEC50-X)×HillSlope ); X, analyte concentration; top, Y max ; bottom, Y min ; EC 50 , concentration of agonist that gives a response halfway between bottom and top). The HillSlope parameter was constrained to 1.0. An R 2 value to quantify goodness of fit (range 0-1.0) and an IC 50 value were reported.
Luciferase reporter assay. LLC-PK1 cells, or C2C12 cells stably transfected with a BRE-luciferase reporter plasmid 85 , were plated in complete DMEM supplemented with 10% FBS at a density of 5 × 10 4 cells/ml in a 96-well plate (100 µl/well) (Nunc-Immuno MicroWell 96-well polystyrene plates, Sigma-Aldrich). After 24 h, LLC-PK1 cells were transfected with Lipofectamine 2000 transfection reagent (Life Technologies) according to the manufacturer's protocol, with 40 ng pGL3 BRE-Luc plasmid 86 , 30 ng Renilla control plasmid and, where indicated, 20 ng of empty pHLsec vector control or test constructs as indicated. Eight hours after transfection, the cells were washed with PBS (100 µl) and serum starved overnight in complete DMEM supplemented with 0.1% FBS. Cells were stimulated with 6 nM, 10 nM or 25 nM BMP2, as indicated, or buffer. When soluble proteins were directly added to the cells, BMP2 was preincubated with a dilution series (from 0.4 to 100 times the molar concentration of BMP2) of eBMPR1A or eRGMB. After 48-h incubation, cells were washed with PBS and lysed, and luciferase activity was measured with a dual luciferase assay system (Promega) according to the manufacturer's instructions. Luminescence was quantified with a luminometer (Tecan, Infinite 200 PRO). Graphs were produced and statistical tests carried out with GraphPad Prism Version 6.04 (GraphPad Software).
Sample preparation for microscopy. Prior to imaging, 40 nM BMP2 solution was dialyzed against phenol red-free complete DMEM supplemented with 0.1% FBS to remove 10 mM ammonium acetate buffer. COS7 cells were seeded at a density of 1 × 10 5 cells/ml in glass-bottomed dishes (2 ml) (MatTek). After 24 h, cells were transfected with 1.5 µg NEO1-mVenus and 1.5 µg full-length RGMB with Lipofectamine 2000 transfection reagent (Life Technologies) according to the manufacturer's protocol. Eight hours after transfection, the cells were serum-starved overnight in phenol red-free complete DMEM supplemented with 0.1% FBS. Prior to imaging, cell medium was replaced with either 20 nM BMP2containing medium or blank medium. Live-cell imaging was carried out immediately. For fixed samples, the BMP2 or blank medium was removed after the indicated amount of time, and cells were fixed with 4% paraformaldehyde (PFA) (10 min, room temperature) and washed thoroughly in PBS to remove excess PFA before being stored in PBS at 4 °C.
Imaging. Images were acquired on a total internal reflection fluorescence microscope (TIRFM) (ELYRA; Zeiss) with a 100× oil-immersion objective with a numerical aperture of 1.46. For illumination/photoconversion, 30% transmission of the 488-nm laser and 1% transmission of the 405-nm laser were used, and 5,000-10,000 images were acquired per sample with a cooled, electron-multiplying charge-coupled-device camera (iXon DU-897D; Andor). Exposure time was 300 ms. Recorded images were analyzed with Zeiss ZEN software. dSTORM data processing. Raw fluorescence-intensity images were analyzed with Zen 2010D (Zeiss MicroImaging). A Gaussian and Laplace filter was applied to each frame, and overlapping events were excluded. An event was classified as originating from a single molecule when I − M > 6S (with I representing event intensity, M mean image intensity, and S the s.d. of image intensity). The center of each point-spread function was then calculated by fitting to a two-dimensional Gaussian distribution, and a table containing the x-y particle coordinates of each molecule was extracted. Regions of interest, 5 µm × 5 µm or 3 µm × 3 µm in area, containing the two-dimensional molecular coordinates, were cropped for analysis with Origin, and events with localization precision worse than 60 nm were discarded. Areas containing ~300 molecules for live-cell imaging and ~1,000 events for the fixed samples were selected. To analyze the spatial point pattern, we used Ripley's K function, calculated with SpPack 87 and the Spatstat package for R software (http://www.R-project.org/), and plotted the L function as described 88, 89 . Briefly, Ripley's K function is a measure of the number of points encircled by concentric circles of radius r centered on each point. K values from the Ripley function therefore scale with circle area and so are transformed into the L function. With this equation, scaling is linear with the radius. Random distributions have an L(r) value of r over all r values. Therefore, to analyze levels of clustering we plotted L(r) against r; and positive values at a given r indicate clustering at that spatial scale. Quantitative cluster maps were generated with Getis and Frankin's analysis as previously described 88, 89 . Briefly, L(r) values at a spatial scale of 50 nm (L(50)) were computed for each point with R and interpolated with Origin to produce a quantitative cluster map. This was then pseudocolored with ImageJ (http://imagej.nih.gov/ij/) to highlight regions of high clustering. Live-cell dSTORM images were constructed with a time-gated window approach 90, 91 . On the basis of the frame number from the raw-data acquisition, cluster maps were generated from 5,000 continuous frames, with each cluster map shifted by 2,000
